Precision BioSciences Wins Patent Challenge Relating to CAR-T Engineering
On Thursday, October 15, Precision BioSciences announced (press release) that the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has ruled in favor of Precision. The ruling resulted from two patent interference proceedings that challenged nine U.S. patents owned by Precision. Below, Celltelligence provides brief thoughts on the patent win for Precision.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.